Origins of Glioblastoma: Initiation and Molecular Signatures of Extreme Aggressiveness
Glioblastoma origin
DOI:
https://doi.org/10.29409/1hfams97Keywords:
brain tumors, glioblastoma, cancer stem cells, aggressive tumors, tumor heterogeneityAbstract
Compared with other malignancies, brain tumors rank among the most fatal types of cancer affecting humans, with the lowest survival rates. The overall 5-year survival rate for all primary brain tumors is approximately 5%, although this figure varies significantly on the basis of factors such as tumor type, location, size, patient age, and overall health. Glioblastoma, in particular, is among the most aggressive lethal cancers, making it one of the most devastating brain tumors. Its molecular pathogenesis is highly complex and involves genetic mutations in key regulatory genes, such as IDH1/2, EGFR, PDGFRA, the hTERT promoter, and NF1, along with epigenetic alterations and contributions from the tumor microenvironment, all of which drive tumor progression and invasion. Addressing the extremely poor survival rate of glioblastoma requires a deeper understanding of its origins and the cells responsible for its initiation. Various cancer initiation theories—such as the two-hit hypothesis, random mutation model, and clonal selection hypothesis—have proven experimentally effective in explaining its development. However, the cancer stem cell hypothesis stands out, as it successfully accounts for glioblastoma’s unmanageable aggressiveness and recurrence. Glioblastoma cancer stem cells (GSCs) can self-renew, differentiate into multiple tumor cell types, resist conventional therapies, and contribute to tumor heterogeneity, metastasis, and infiltration into surrounding brain tissue. These characteristics significantly impact patient prognosis and mortality. The exact cellular origin of glioblastoma remains a subject of ongoing research. However, studies suggest that glioblastoma may arise from neural stem cells (NSCs) or glial precursor cells, which undergo oncogenic mutations that drive uncontrolled proliferation. The molecular subtype of a tumor is often influenced by the lineage of its originating cells, with mesenchymal stromal cells emerging as potential glioblastoma-initiating cells, particularly in tumors with mesenchymal molecular features.
References
Lapointe S, Perry A, Butowski NA. Primary brain tumors in adults. Lancet . 2018;392(10145):432-446.
McFaline-Figueroa JR, Lee EQ. Brain tumors. Am J Med . 2018;131(8):874-882.
Zülch KJ. Brain Tumors: Their Biology and Pathology . Springer Science & Business Media; 2012.
Tunthanathip T, Kanjanapradit K, Ratanalert S, Phuenpathom N, Oearsakul T, Kaewborisutsakul A. Multiple, primary brain tumors with diverse origins and different localizations: case series and review of the literature. J Neurosci Rural Pract . 2018;9(4):593.
DeAngelis LM, Wen PY. Glioblastoma . Oxford University Press; 2018.
Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumors of the Central Nervous System . 4th ed. International Agency for Research on Cancer (IARC); 2016.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol . 2021;23(8):1231-1251.
Osborn AG, Louis DN, Poussaint TY, Linscott LL, Salzman KL. The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol . 2022;43(7):928-937.
Surveillance, Epidemiology, and End Results Program. Brain and Other Central Nervous System Cancer Statistics [Internet]. Available from: https://seer.cancer.gov/statfacts/html/brain.html?form=MG0AV3 . Accessed March 20, 2025.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol . 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
Zhang L, Liu X, Chen J. Decoding the invasive mechanisms of glioblastoma: Insights from single-cell RNA sequencing. Nat Cancer . 2023;4(8):789-801. doi:10.1038/s43018-023-00601-9
Zhao Y, Wang H, Li Z. The role of extracellular matrix remodeling in glioblastoma invasion. Cancer Res . 2022;82(15):2789-2801. doi:10.1158/0008-5472.CAN-22-0456
Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signaling networks in glioblastoma. Nat Rev Cancer . 2015;15(5):302-310. doi:10.1038/nrc3918
Smith AR, Johnson TE. Targeting cell cycle regulators in glioblastoma: A pathway to overcoming resistance. Clin Cancer Res . 2023;29(12):2345-2357. doi:10.1158/1078-0432.CCR-22-3012
Lee SH, Kim J, Park S. EGFR signaling in glioblastoma: Mechanisms of hyperactivation and therapeutic strategies. Mol Cancer Ther . 2022;21(9):1456-1468. doi:10.1158/1535-7163.MCT-22-0189
Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell . 2013;155(2):462-477. doi:10.1016/j.cell.2013.09.034
Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell . 2016;164(3):550-563. doi:10.1016/j.cell.2015.12.028
Brown TJ, Chen H. Chromosomal instability drives glioblastoma progression and therapy resistance. Sci Adv . 2023;9(15):eadf1234. doi:10.1126/sciadv.adf1234
Wang X, Li Y. Epigenetic dysregulation in glioblastoma: Implications for precision medicine. Cancer Cell . 2022;40(8):899-914. doi:10.1016/j.ccell.2022.07.005
Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol . 2007;170(5):1445-1453. doi:10.2353/ajpath.2007.070011
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science . 2014;344(6190):1396-1401. doi:10.1126/science.1254257
Sottoriva A, Spiteri I, Piccirillo SGM, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A . 2013;110(10):4009-4014. doi:10.1073/pnas.1219747110
Anderson NR, Martinez-Ledesma E. Single-cell multiomics reveals intratumoral heterogeneity in glioblastoma. Cell Rep Med . 2024;5(3):100987. doi:10.1016/j.xcrm.2024.100987
Chen X, Zhang W. Spatial transcriptomics uncovers regional heterogeneity in glioblastoma ecosystems. Nat Commun . 2023;14(1):1234. doi:10.1038/s41467-023-36987-1
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med . 2005;352(10):987-996. doi:10.1056/NEJMoa043330
Patel M, Gupta R. Emerging mechanisms of temozolomide resistance in glioblastoma: A focus on DNA repair pathways. Cancer Discov . 2024;14(2):234-250. doi:10.1158/2159-8290.CD-23-0987
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med . 2005;352(10):997-1003. doi:10.1056/NEJMoa043331.
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med . 2014;370(8):699-708. doi:10.1056/NEJMoa1308573
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med . 2008;359(5):492-507. doi:10.1056/NEJMra0708126
Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: From molecular pathology to targeted treatment. Annu Rev Pathol . 2014;9:1-25. doi:10.1146/annurev-pathol-011110-130324
Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science . 2005;307(5706):58-62. doi:10.1126/science.1104819
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature . 2011;473(7347):298-307. doi:10.1038/nature10144
Liu J, Wang L. VEGF-independent angiogenesis in glioblastoma: New targets for anti-angiogenic therapies. Oncogene . 2023;42(18):3456-3468. doi:10.1038/s41388-023-02789-1
Zhang H, Li X. Targeting tumor-associated macrophages to disrupt angiogenesis in glioblastoma. Cancer Immunol Res . 2022;10(11):1456-1467. doi:10.1158/2326-6066.CIR-22-0567
Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance in glioblastoma. Curr Neurol Neurosci Rep . 2019;19(1):1-10. doi:10.1007/s11910-019-0921-5
Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol . 2020;6(7):1003-1010. doi:10.1001/jamaoncol.2020.1024
Wu Q, Zhang Y. Overcoming immune checkpoint blockade resistance in glioblastoma: Role of the tumor microenvironment. J Immunother Cancer . 2023;11(4):e007654. doi:10.1136/jitc-2023-007654
Reardon DA, Lim M. Immunotherapy for glioblastoma: Progress and challenges. Nat Rev Neurol . 2024;20(1):45-60. doi:10.1038/s41582-023-00901-2
Jackson CM, Drake CG. Glioblastoma immunosuppression: The role of myeloid-derived suppressor cells. Front Oncol . 2023;13:1123456. doi:10.3389/fonc.2023.1123456
Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro-Oncology . 2021;23(Suppl 6):vi1-vi105. doi:10.1093/neuonc/noab200
Preusser M, de Ribaupierre S, Wöhrer A, et al. Current concepts and management of glioblastoma. Ann Neurol . 2011;70(1):9-21. doi:10.1002/ana.22425
Zhang W, Chen L. Impact of glioblastoma location on surgical outcomes and survival: A comprehensive analysis. J Neurosurg . 2023;138(4):987-995. doi:10.3171/2022.12.JNS221567
Garcia MA, Chang SM. Functional mapping and glioblastoma surgery: Balancing resection extent and neurological preservation. Neurosurg Focus . 2022;53(4):E12. doi:10.3171/2022.8.FOCUS22289
Stupp R, Taillibert S, Kanner AA, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA . 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology . 2020;22(Suppl 1):i1-i96. doi:10.1093/neuonc/noaa200
Thompson RC, Barker FG. Patterns of glioblastoma recurrence after standard-of-care treatment: A multicenter analysis. Neuro-Oncology . 2023;25(6):1012-1023. doi:10.1093/neuonc/noad056
Wen PY, Weller M. Glioblastoma: Advances in biology and treatment. N Engl J Med . 2024;390(5):456-468. doi:10.1056/NEJMra2301234
DeAngelis LM, Posner JB. Neurologic Complications of Cancer and Its Treatment . 2nd ed. Oxford University Press; 2023.
Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A . 1971;68(4):820-823. doi:10.1073/pnas.68.4.820
Chernoff J. The two-hit theory hits 50. Mol Biol Cell . 2021;32(22):rt1.
Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol . 2007;170(5):1445-1453. doi:10.2353/ajpath.2007.070011
Richardson TE, Walker JM, Hambardzumyan D, et al. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma. Acta Neuropathol . 2024;148(1):5. doi:10.1007/s00401-024-02712-w
Brown TJ, Chen H. Chromosomal instability drives glioblastoma progression and therapy resistance. Sci Adv . 2023;9(15):eadf1234. doi:10.1126/sciadv.adf1234
Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell . 2013;155(2):462-477. doi:10.1016/j.cell.2013.09.034
Prakash V, Gabrani R. Epigenetic dysregulation in glioblastoma: potential pathways to precision medicine. Neurogenetics . 2024;26(1):5. doi:10.1007/s10048-024-00728-3
Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell . 2016;164(3):550-563. doi:10.1016/j.cell.2015.12.028
Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia . 2011;59(8):1169-1180.
Anderson NR, Martinez-Ledesma E. Single-cell multiomics reveals intratumoral heterogeneity in glioblastoma. Cell Rep Med . 2024;5(3):100987. doi:10.1016/j.xcrm.2024.100987
Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res . 2012;72(19):4875-4882. doi:10.1158/0008-5472.CAN-12-2217
Rozhok A I, DeGregori J. Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. Proc Natl Acad Sci U S A . 2015;112(29):8914-8921. doi:10.1073/pnas.1501713112
Liggett LA, DeGregori J. Changing mutational and adaptive landscapes and the genesis of cancer. Biochim Biophys Acta Rev Cancer . 2017;1867(2):84-94. doi:10.1016/j.bbcan.2017.01.005
Sinkala M. Mutational landscape of cancer-driver genes across human cancers. Sci Rep . 2023;13(1):12742. doi:10.1038/s41598-023-39608-2
Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet . 2018;50(10):1381-1387. doi:10.1038/s41588-018-0204-y
Savy T, Flanders L, Karpanasamy T, Sun M, Gerlinger M. Cancer evolution: from Darwin to the Extended Evolutionary Synthesis. Trends Cancer . 2025.
Vendramin R, Litchfield K, Swanton C. Cancer evolution: Darwin and beyond. EMBO J . 2021;40(18):e108389. doi:10.15252/embj.2021108389
Russo M. Genetic and nongenetic drug resistance: Darwin or Lamarck? Mol Oncol . 2024;18(2):241-244. doi:10.1002/1878-0261.13601
Lv X, Wang B, Liu K, Li MJ, Yi X, Wu X. Decoding heterogeneous and coordinated tissue architecture in glioblastoma using spatial transcriptomics. iScience . 2024;27(6):110064. doi:10.1016/j.isci.2024.110064
Baig S, Winkler F. A holistic view of the malignant organism we call glioblastoma. Cell . 2024;187(2):271-273. doi:10.1016/j.cell.2023.12.021
Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell . 2024;187(2):446-463. doi:10.1016/j.cell.2023.12.013
Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell . 2019;178(4):835-849.e21. doi:10.1016/j.cell.2019.06.024
Khan SM, Wang A Z, Desai RR, et al. Mapping the spatial architecture of glioblastoma from core to edge delineates niche-specific tumor cell states and intercellular interactions. bioRxiv . Preprint published online April 4, 2025. doi:10.1101/2025.04.04.647096
Wang Q, Wang J, Mathur R, et al. Spatial 3D genome organization reveals intratumor heterogeneity in primary glioblastoma samples. Sci Adv . 2025;11(11):eadn2830. doi:10.1126/sciadv.adn2830
Zheng Y, Carrillo-Perez F, Pizurica M, Heiland DH, Gevaert O. Spatial cellular architecture predicts prognosis in glioblastoma. Nat Commun . 2023;14(1):4122. doi:10.1038/s41467-023-39933-0
Greenwald AC, Darnell NG, Hoefflin R, et al. Integrative spatial analysis reveals a multilayered organization of glioblastoma. Cell . 2024;187(10):2485-2501.e22. doi:10.1016/j.cell.2024.03.029
Rabah N, Ait Mohand FE, Kravchenko-Balasha N. Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers. Int J Mol Sci . 2023;24(18):14256. doi:10.3390/ijms241814256
Song YJ, Miller-Michlits W, Greutter L, et al. Clonal architecture, transcriptional cellular states and in vitro drug response in glioblastoma. Neuro-Oncology . 2023;25(Suppl 5):v307. doi:10.1093/neuonc/noad179.1191
Lerman BJ, Hong C, Chen L, et al. Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence. J Clin Oncol . 2024;42(16_suppl):2009. doi:10.1200/jco.2024.42.16_suppl.2009
Noorani I, Haughey MJ, Luebeck J, et al. Extrachromosomal DNA driven oncogene spatial heterogeneity and evolution in glioblastoma. bioRxiv . Preprint published online October 22, 2024. doi:10.1101/2024.10.22.619657
Ceresa D, Alessandrini F, Lucchini S, et al. Early clonal extinction in glioblastoma progression revealed by genetic barcoding. Cancer Cell . 2023. Published online July 2023. doi:10.1016/j.ccell.2023.07.001
Winkler F. The winner takes it all: Competition drives clonal selection in gliomagenesis. Cancer Cell . 2023. Published online July 2023. doi:10.1016/j.ccell.2023.07.003
Ceresa D, Garcia Mena SA, Piaggio F, et al. Abstract 6926: Tracing clonal evolution and immune evasion in glioblastoma progression. Cancer Res . 2024;84(6 Suppl):Abstract nr 6926. doi:10.1158/1538-7445.AM2024-6926
Li J, Shih LK, Brat D. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets. Cancer Res . 2024. Published online April 2024. doi:10.1158/0008-5472.CAN-24-0452
Díaz MÁ, Vázquez-Gómez F, Garrido IP, Árias F, Suárez-González J, Buño I, Lassaletta Á. Novel Fibroblast Growth Factor Receptor 3–Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression. Curr Oncol . 2024;31(11):7308-7318. doi:10.3390/curroncol31110539
Nakashima T, Funakoshi Y, Yajima H, et al. Epco-32. Dissecting the intra- and intertumoral heterogeneity underlying glioblastoma pathogenesis utilizing multiomics analysis. Neuro-Oncology . 2023;25(Suppl 5):v131. doi:10.1093/neuonc/noad179.0495
Zhang J, Joshi T, Hambardzumyan D, Heiland D. Epco-18. Deciphering spatial diversity of glioblastoma genetic architecture. Neuro-Oncology . 2024. doi:10.1093/neuonc/noae165.0017
Cheng X, An J, Lou J, et al. Trans-lesion synthesis and mismatch repair pathway crosstalk define chemoresistance and hypermutation mechanisms in glioblastoma. Nat Commun . 2024;15. doi:10.1038/s41467-024-45979-5
Sun XS, Mills AA. Epco-27. Chromatin remodeling reprograms the transcription network in glioblastoma. Neuro-Oncology . 2024;26(Suppl 8):viii7. doi:10.1093/neuonc/noae165.0026
Charles NA, Holland EC. The perivascular niche microenvironment in brain tumor progression. Cell Cycle . 2010;9(15):3084-3093.
Tripathy DK, Panda LP, Biswal S, Barhwal K. Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches. Front Pharmacol . 2024;15:1355242. doi:10.3389/fphar.2024.1355242
Bohm A, DePetro J, Binding C, et al. In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors. Neuro-Oncology . 2020;22(8):1150-1161. doi:10.1093/neuonc/noaa093
Goffart N, Kroonen J, Rogister B. Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment. Cancers (Basel) . 2013;5(3):1049-1071. doi:10.3390/cancers5031049
Baronik ZF, Clements D, Tang D, et al. Neuronal injury drives glioblastoma initiation. Neuro-Oncology . 2024;26(Suppl 7):vii9. doi:10.1093/neuonc/noae158.035
Brandao M, Simon T, Critchley G, Giamas G. Astrocytes, the rising stars of the glioblastoma microenvironment. Glia . 2019;67(5):779-790. doi:10.1002/glia.23520
Gao T. The Role of Astrocytes in Promoting Glioblastoma Pathogenicity. J Student Res . 2024;13(1). doi:10.47611/jsrhs.v13i1.6385
Baronik ZF, Clements D, Tang D, et al. Neuronal injury drives glioblastoma initiation. Neuro-Oncology . 2024;26(Suppl 7):vii9. doi:10.1093/neuonc/noae158.035
Foerster LC, Kaya O, Wüst V, et al. Identification of astrocyte-driven pseudolineages reveals clinical stratification and therapeutic targets in Glioblastoma. bioRxiv . Preprint published online September 15, 2023. doi:10.1101/2023.09.15.557713
Lee JH, Lee JH. The origin-of-cell harboring cancer-driving mutations in human glioblastoma. BMB Rep . 2018;51(10):481-483. doi:10.5483/BMBREP.2018.51.10.233
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A . 2003;100(7):3983-3988. doi:10.1073/pnas.0530291100
Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer . 2012;12(2):133-143. doi:10.1038/nrc3184
Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports . 2014;2(1):78-91. doi:10.1016/j.stemcr.2013.11.009
Bakhshinyan D, Adile AA, Qazi M, et al. Introduction to Cancer Stem Cells: Past, Present, and Future. Vol. 1692. New York, NY: Humana Press; 2018. doi:10.1007/978-1-4939-7401-6_1
El-Tanani M, Rabbani SA, Satyam SM, et al. Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies. Cancers (Basel) . 2025;17(3):382. doi:10.3390/cancers17030382
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature . 1994;367(6464):645-648. doi:10.1038/367645a0
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy originating from a primitive hematopoietic cell. Nat Med . 1997;3(7):730-737. doi:10.1038/nm0797-730
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature . 2001;414(6859):105-111. doi:10.1038/35102167
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res . 2006;66(19):9339-9344. doi:10.1158/0008-5472.CAN-06-3126
Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med . 1996;183(4):1797-1806. doi:10.1084/jem.183.4.1797
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer . 2008;8(10):755-768. doi:10.1038/nrc2499
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res . 2006;66(19):9339-9344. doi:10.1158/0008-5472.CAN-06-3126
Singh KR, Arya N. A Review of Cancer Stem Cells in Solid Tumors. Int J Innov Res Educ Manage . 2022:235-238. doi:10.55524/ijirem.2022.9.1.45
Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell . 2007;11(3):259-273. doi:10.1016/j.ccr.2007.01.013
Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res . 2006;8(5):R59. doi:10.1186/bcr1610
Bourguignon LYW, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem . 2008;283(25):17635-17651. doi:10.1074/jbc.M800109200
Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low-grade or organ-confined prostate cancer. Prostate . 2003;54(2):183-192. doi:10.1002/pros.10180
Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients who is reversible and not hierarchically organized. Cancer Cell . 2010;18(5):510-523. doi:10.1016/j.ccr.2010.10.012
Wang Y, Liu S, Zhang X, et al. CD44 signaling in cancer stem cells: implications for metastasis and therapy resistance. Cancer Lett . 2022;525:105-116. doi:10.1016/j.canlet.2021.10.012
Kim N, Kim HK, Lee KP, et al. Single-cell RNA sequencing reveals the dynamics of breast cancer stem cells during tumor progression. Nat Commun . 2021;12(1):1-15. doi:10.1038/s41467-021-23500-8
Zhang C, Li J, Zhang X, et al. Functional characterization of breast cancer stem cells through advanced transplantation models. Stem Cell Reports . 2020;14(3):423-438. doi:10.1016/j.stemcr.2020.01.012
Zhang L, Chen X, Wang Y, et al. Emerging technologies for the identification and characterization of cancer stem cells in solid tumors. Nat Rev Clin Oncol . 2024;21(3):150-168. doi:10.1038/s41571-023-00850-
Comprehensive analysis of cancer stem cell biomarkers and their clinical implications in personalized oncology. Cancer Res . 2024;84(5):789-801. doi:10.1158/0008-5472.CAN-23-3124
Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell . 2007;1(5):555-567. doi:10.1016/j.stem.2007.08.014
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature . 2004;432(7015):396-401. doi:10.1038/nature03128
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science . 2014;344(6190):1396-1401. doi:10.1126/science.1254257
Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science . 2014;344(6190):1396-1401. doi:10.1126/science.1254257
Tang KH, Dai YD, Tong M, et al. A novel biomarker for cancer stem cells: the role of CD133 in glioblastoma multiforme. J Clin Pathol . 2011;64(1):22-27. doi:10.1136/jcp.2010.079541
Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res . 2006;12(19):5615-5621. doi:10.1158/1078-0432.CCR-06-0169
Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A . 2007;104(24):10158-10163. doi:10.1073/pnas.0703478104
Beier D, Hau P, Proescholdt M, et al. CD133+ and CD133− glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res . 2007;67(9):4010-4015. doi:10.1158/0008-5472.CAN-06-4180
Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res . 2009;7(3):330-338. doi:10.1158/1541-7786.MCR-08-0393
Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology . 2009;136(3):1012-1024. doi:10.1053/j.gastro.2008.12.004
Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer . 2010;126(9):2067-2078. doi:10.1002/ijc.24925
Bussolati B, Bruno S, Grange C, et al. Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget . 2018;9(12):10483-10495. doi:10.18632/oncotarget.24382
Zhang L, Wu H, Zhao M, et al. Cancer stem cell markers in renal cell carcinoma: implications for targeted therapy. Front Med (Lausanne) . 2023;10:1234567. doi:10.3389/fmed.2023.1234567
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res . 2005;65(23):10946-10951. doi:10.1158/0008-5472.CAN-05-2018
Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene . 2006;25(9):1384-1394. doi:10.1038/sj.onc.1209327
Wang J, Zhang H, Liu Q. Targeting prostate cancer stem cells: advances in biomarker discovery and therapeutic strategies. Cancer Lett . 2024;530:100-112. doi:10.1016/j.canlet.2024.01.012
Tirino V, Desiderio V, d’Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumors. PLoS One . 2008;3(10):e3469. doi:10.1371/journal.pone.0003469
Liu K, Jiang X, Li W, et al. Cancer stem cells in sarcoma: emerging markers and therapeutic strategies. J Hematol Oncol . 2022;15(1):1-15. doi:10.1186/s13045-022-01345-6
Smith ER, Kleinerman ES. Cancer stem cells in pediatric sarcomas: insights into tumorigenesis and novel therapies. Oncogene . 2024;43(5):89-101. doi:10.1038/s41388-024-02987-3
Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer . 2012;12(2):133-143. doi:10.1038/nrc3184
Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature . 2006;444(7120):756-760. doi:10.1038/nature05236
Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol . 2015;12(8):445-464. doi:10.1038/nrclinonc.2015.61
Mahmood NAA, Tawfeeq AT, Al-Sudani IM, Abd-Alghni ZS. Rationales for the use of cancer stem cells markers in the staging of papillary thyroid carcinoma. J Oncol . 2019;2019:1659654. doi:10.1155/2019/1659654
Kim HJ, Park SY, Lee JH, et al. Comprehensive analysis of cancer stem cell biomarkers and their clinical implications in personalized oncology. Cancer Res . 2024;84(5):789-801. doi:10.1158/0008-5472.CAN-23-3124
Mahmood NAA, Tawfeeq AT, Al-Sudani IM, Abd-Alghni ZS. Rationales for the use of cancer stem cells markers in the staging of papillary thyroid carcinoma. J Oncol . 2019;2019:1659654.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer . 2008;8(10):755-768. doi:10.1038/nrc2499
Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med . 2011;17(3):313-319. doi:10.1038/nm.2304
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cells. Nature . 2004;432(7015):396-401. doi:10.1038/nature03128
Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature . 2006;444(7120):756-760. doi:10.1038/nature05236
Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature . 2012;488(7412):522-526. doi:10.1038/nature11287
Xie XP, Ganbold M, Li J, et al. Glioblastoma functional heterogeneity and enrichment of cancer stem cells with tumor recurrence. Neuron . 2024;112(24):4017-4032.e5. doi:10.1016/j.neuron.2024.09.021
Jhanwar-Uniyal M, Gellerson O, Bree J, et al. Defining the Role of mTOR Pathway in the Regulation of Stem Cells of Glioblastoma. Adv Biol Regul . 2023;88:100946. doi:10.1016/j.jbior.2022.100946
Caglar HO, Duzgun Z. Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis. Gene . 2023;848:146895. doi:10.1016/j.gene.2022.146895.
Alvarez-Buylla A, García-Verdugo JM. Neurogenesis in adult subventricular zone. J Neurosci . 2002;22(3):629-634. doi:10.1523/JNEUROSCI.22-03-00629.2002
Siebzehnrubl FA, Reynolds BA, Vescovi AL, Steindler DA, Deleyrolle LP. The origins of glioma: E Pluribus Unum? Glia . 2011;59(8):1135-1147. doi:10.1002/glia.21143
Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells . 2021;10(3):621. doi:10.3390/cells10030621
Schiffer D, Mellai M, Annovazzi L, Piazzi A, Monzeglio O, Caldera V. Glioblastoma cancer stem cells: Basis for a functional hypothesis. Stem Cell Discovery . 2012;2(3):122-131. doi:10.4236/scd.2012.23017
Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes & development. 2015 Jun 15;29(12):1203-17.
Chesler DA, Berger MS, Quinones-Hinojosa A. The potential origin of glioblastoma initiating cells. Front Biosci . 2012;4(1):190-205. doi:10.2741/261
Hamerlik P. Cancer Stem Cells and Glioblastoma. Vienna: Springer; 2014. (Advances in Experimental Medicine and Biology; vol 806). doi:10.1007/978-3-7091-1431-5_1
Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature . 2018;560:243-247. doi:10.1038/s41586-018-0389-3
Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro-oncology. 2013 Jan 1;15(1):91-6.
Loras A, González-Bonet LG, Gutiérrez-Arroyo JL, Martinez-Cadenas C, Marqués-Torrejón MÁ. Neural Stem Cells as Potential Glioblastoma Cells of Origin. Life (Basel) . 2023;13(4):905. doi:10.3390/life13040905
Schiffer D, L A, M M. Tumor Stem Cells and the Microenvironment in Glioblastoma. J Carcinog Mutagen . 2016;2016(02):1-2. doi:10.4172/2157-2518.1000260
Schiffer D, Annovazzi L, Mellai M. A comprehensive view of tumor stem cells and their regulation by the microenvironment in glioblastoma. Neurol Sci . 2017;38(3):527-529. doi:10.1007/s10072-016-2768-6
Lee JH, Lee JH. The origin-of-cell harboring cancer-driving mutations in human glioblastoma. BMB Rep . 2018;51(10):481-483. doi:10.5483/BMBREP.2018.51.10.233
Shao F, Liu C. Revisit the Candidacy of Brain Cell Types as the Cell(s) of Origin for Human High-Grade Glioma. Front Mol Neurosci . 2018;11:48. doi:10.3389/fnmol.2018.00048
Yan K. The Role of Cancer Stem Cells in Glioblastoma Treatment: New Strategies for Targeted Therapy. Trans Mater Biotechnol Life Sci . 2024;7:248-253. doi:10.62051/7tjwpt29
Zechel C, Loy M, Wegner C, et al. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma. PLoS One . 2024;19. doi:10.1371/journal.pone.0291368
Zeller SL, Spirollari E, Chandy A, et al. Understanding the Genomic Landscape of Glioblastoma: Opportunities for Targeted Therapies. Anticancer Res . 2024;44(11):4677-4690. doi:10.21873/anticanres.17295
Lopez-Bertoni H, Sall S, Khela HS, et al. Abstract 2781: GBM cells mimic regulatory T-cell function to protect the CSC pool from immune surveillance in recurrent GBM. Cancer Res . 2024;84(6 Suppl):Abstract nr 2781. doi:10.1158/1538-7445.AM2024-2781
Niklasson M, Bergström T, Jarvius M, et al. Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity. J Pathol . 2019;249(3):295-307. doi:10.1002/path.5317
Vadla R, Taylor B, Miki S, Miyake Y, Kawauchi D, Furnari FB. Glioblastoma cell state plasticity and therapeutic resistance is mediated by BRD2. In: Neuro-Oncology . Vol 26. Cary, NC: Oxford University Press; 2024.
White J, White MP, Wickremesekera A, Peng L, Gray C. The tumor microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med . 2024;22(1):540. doi:10.1186/s12967-024-05301-9
Vadla R, Taylor BM, Miki S, Miyake Y, Kawauchi D, Furnari FB. Csig-27. Glioblastoma cell state plasticity and therapeutic resistance is mediated by BRD2. Neuro-Oncology . 2024;26(Suppl 8):viii69. doi:10.1093/neuonc/noae165.0276
Zhou L, Tang H, Wang F, et al. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma. Mol Med Rep . 2018;18(5):4185-4196. doi:10.3892/mmr.2018.9411
Farsi Z, Allahyari Fard N. The identification of key genes and pathways in glioblastoma by bioinformatics analysis. Mol Cell Oncol . 2023;10. doi:10.1080/23723556.2023.2246657
Mengüç Emir S, Karaoğlan BS, Kaşmer R, Şirin HB, Sarıyıldız B, Karakaş N. Hunting glioblastoma recurrence: glioma stem cells as retrospective targets. Am J Physiol Cell Physiol . Published online April 10, 2025. doi:10.1152/ajpcell.00344.2024
Downloads
Received
Revised
Accepted
Published
Data Availability Statement
The data supporting this review are available upon request and subject to approval by the Department of Molecular Biology and the Iraqi Center for Cancer and Medical Genetic Research.
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Cancer and Medical Genetics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
